Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. A Phase 3 withdrawal/re‐treatment study (NCT01186744; OPT Retreatment) showed tofacitinib re‐treatment was effective in patients with chronic plaque psoriasis. OBJECTIVES: To describe the effects of tofacitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffiths, C.E.M., Vender, R., Sofen, H., Kircik, L., Tan, H., Rottinghaus, S.T., Bachinsky, M., Mallbris, L., Mamolo, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Psoriasis and Autoimmune Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297866/
https://www.ncbi.nlm.nih.gov/pubmed/27600367
http://dx.doi.org/10.1111/jdv.13808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297866/
https://www.ncbi.nlm.nih.gov/pubmed/27600367
http://dx.doi.org/10.1111/jdv.13808

Ejemplares similares